Vaxart (VXRT) News Today $0.70 +0.17 (+30.73%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.67 -0.03 (-4.27%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - Should You Sell?June 14 at 3:13 AM | marketbeat.comVaxart Announces Preliminary Results of Annual Meeting of StockholdersJune 13 at 4:52 PM | globenewswire.comVaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJune 11 at 7:30 AM | globenewswire.comVaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus TrialJune 10, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) vs. LadRx (OTCMKTS:CYTR) Financial ReviewJune 10, 2025 | americanbankingnews.comVaxart, Inc. (NASDAQ:VXRT) Sees Significant Growth in Short InterestJune 5, 2025 | americanbankingnews.comVaxart, Inc. (NASDAQ:VXRT) Sees Significant Increase in Short InterestVaxart, Inc. (NASDAQ:VXRT - Get Free Report) saw a significant growth in short interest in May. As of May 15th, there was short interest totalling 14,350,000 shares, a growth of 19.1% from the April 30th total of 12,050,000 shares. Currently, 6.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,030,000 shares, the short-interest ratio is currently 7.1 days.June 4, 2025 | marketbeat.comMillennium Management LLC Decreases Stock Holdings in Vaxart, Inc. (NASDAQ:VXRT)Millennium Management LLC trimmed its holdings in Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 24.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,990,642 shares of the biotechnology company'sJune 3, 2025 | marketbeat.comVaxart Announces Adjournment of Annual Meeting of StockholdersJune 2, 2025 | globenewswire.comB. Riley Has Positive Forecast for Vaxart Q3 EarningsVaxart, Inc. (NASDAQ:VXRT - Free Report) - Research analysts at B. Riley boosted their Q3 2025 earnings per share estimates for shares of Vaxart in a report issued on Thursday, May 29th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnings per share of ($0.0June 2, 2025 | marketbeat.comB. Riley Weighs in on Vaxart's FY2029 Earnings (NASDAQ:VXRT)Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at B. Riley issued their FY2029 earnings per share estimates for Vaxart in a report released on Thursday, May 29th. B. Riley analyst M. Mamtani expects that the biotechnology company will earn $0.13 per share for the year. B. Riley cuMay 31, 2025 | marketbeat.comVaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025May 29, 2025 | globenewswire.comVaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025May 29, 2025 | quiverquant.comVaxart's Founder and Chief Scientific Officer Provides Video Update to StockholdersMay 29, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?May 29, 2025 | marketbeat.comVaxart Discusses Reverse Stock Split and Capital RaiseMay 28, 2025 | tipranks.comVaxart Answers Additional Frequently Asked Questions from Retail InvestorsMay 28, 2025 | globenewswire.comVaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27, 2025 | globenewswire.comWall Street Zen Upgrades Vaxart (NASDAQ:VXRT) to "Hold"Wall Street Zen upgraded shares of Vaxart to a "hold" rating in a report on Thursday.May 24, 2025 | marketbeat.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock NewsMay 20, 2025 | gurufocus.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 SharesMay 20, 2025 | insidertrades.comVaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder MeetingMay 16, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Here's What HappenedVaxart (NASDAQ:VXRT) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?May 16, 2025 | marketbeat.comVaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 15, 2025 | globenewswire.comVaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational MedicineMay 14, 2025 | globenewswire.comVaxart Names Grasman as CFO, Succeeding LeeMay 14, 2025 | marketwatch.comVaxart, Inc. (VXRT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comVaxart Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comVaxart Appoints Jeroen Grasman as Chief Financial OfficerMay 13, 2025 | globenewswire.comVaxart Proposes Reverse Stock Split to Avoid DelistingMay 12, 2025 | tipranks.comVaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy StatementMay 12, 2025 | globenewswire.comVaxart (VXRT) Projected to Post Quarterly Earnings on MondayVaxart (NASDAQ:VXRT) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-vaxart-inc-stock/)May 7, 2025 | marketbeat.comVaxart Resumes COVID-19 Vaccine Trial After Government LiftMay 5, 2025 | tipranks.comVaxart CEO Issues Letter to Stockholders Highlighting Company ProgressMay 5, 2025 | globenewswire.comVaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13May 2, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?May 2, 2025 | marketbeat.comVaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine CandidateApril 30, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - Should You Sell?April 24, 2025 | marketbeat.comVaxartto Present at World Vaccine Congress Washington 2025 on April 23April 16, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - Here's What HappenedVaxart (NASDAQ:VXRT) Shares Pass Below 200 Day Moving Average - Should You Sell?April 10, 2025 | marketbeat.comB. Riley Issues Positive Outlook for Vaxart EarningsVaxart, Inc. (NASDAQ:VXRT - Free Report) - B. Riley lifted their Q1 2025 earnings estimates for Vaxart in a research note issued to investors on Wednesday, March 26th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarteMarch 31, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Price Target Lowered to $2.00 at B. RileyB. Riley cut their target price on Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a report on Thursday.March 28, 2025 | marketbeat.comVaxart price target lowered to $2 from $2.50 at B. RileyMarch 27, 2025 | markets.businessinsider.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | insidermonkey.comVaxart (NASDAQ:VXRT) Announces Earnings Results, Beats Estimates By $0.05 EPSVaxart (NASDAQ:VXRT - Get Free Report) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.05. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.March 21, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Issues Earnings ResultsVaxart (NASDAQ:VXRT - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.March 21, 2025 | marketbeat.comVaxart, Inc. (VXRT) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.com Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Media Mentions By Week VXRT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VXRT News Sentiment▼0.640.88▲Average Medical News Sentiment VXRT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VXRT Articles This Week▼62▲VXRT Articles Average Week Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Solid Biosciences News Today Compass Therapeutics News Today ADC Therapeutics News Today Aquestive Therapeutics News Today SNDL News Today Cryoport News Today Inventiva News Today Arcturus Therapeutics News Today Aurora Cannabis News Today Astria Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VXRT) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
